IGF2BP2 and central nervous system cancer: The above findings were also validated in two other CGGA mRNA datasets (Supplementary Figure S6), which indicates that the expressions of IGF2BP2 and METTL3 and the 12 corresponding targets might serve as prognostic markers for overall survival in glioma patients.